PreveCeutical Medical Inc (QB) (PRVCF)

BioGene Therapeutics Inc. Appoints Ty Howton to Board of DirectorsJune 8, 2026 3:00 AM
NewsfileVancouver, British Columbia--(Newsfile Corp. - June 8, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, today announced that BioGene Therapeutics Inc. (the "Company"or 'BioGene"), a company that is a significant shareholder of, has appointed Ty Howton to BioGene's Board of Directors, effective immediately. Mr. Howton has extensive board and governance experience, having previously served as Board Counsel and Corporate Secretary for Solid Biosciences, AavantiBio, Sarepta Therapeutics, and Vertex Pharmaceuticals, as well as Advisor to the Board on Health Care Compliance at Genentech. He currently serves on the board of Make-A-Wish® Massachusetts and Rhode Island (since March 2021).Mr. Howton is a biopharmaceutical executive with almost 30 years of industry experience, including 15 years serving as an executive team member and lead board advisor for highly successful public and private growth companies. During his career, he has served as an executive at Vertex Pharmaceuticals, Sarepta Therapeutics, and Solid Biosciences, where he was integral to the transition of those companies from clinical-stage to commercial-stage organizations. In his roles, Mr. Howton has facilitated multiple series-stage equity financings, numerous equity offerings, non-dilutive financing arrangements, and debt facilities for public companies. His contributions have supported significant value creation.Mr. Howton currently serves as Chief Operating Officer of Solid Biosciences, where he has built and leads operations for the public clinical-stage neuromuscular/cardiovascular/AAV platform gene therapy company. He established the product development and G&A infrastructure and oversees the day-to-day management of its operations. The company has advanced multiple candidates into active clinical trials, developed a full preclinical pipeline, and significantly grown its market capitalization with a lean organization of fewer than 150 employees.Prior to Solid Biosciences, Mr. Howton served as Chief Operating Officer and General Counsel of AavantiBio, a private gene therapy company backed by a prominent investor syndicate including Bain Capital, Perceptive Lifesciences, and RA Capital, which merged with Solid Biosciences in 2022. His earlier positions include Executive Vice President, General Counsel and Corporate Secretary at Sarepta Therapeutics, Inc., a precision genetic medicine company, where he was a member of the executive team that transformed the company from clinical stage to a multi-drug commercial organization. He also served as Senior Vice President and Chief Legal Officer and Chief Compliance Officer at Vertex Pharmaceuticals, where he was involved in the launches of Incivek and Kalydeco. Prior to Vertex, Mr. Howton held the position of Chief Healthcare Compliance Officer and multiple legal roles at Genentech, Inc.Ty Howton received a Bachelor of Arts in Political Science from Yale University and a Juris Doctor from Northwestern University Pritzker School of Law."I am honored to join the Board of Directors of BioGene Therapeutics," said Ty Howton. "I look forward to contributing my operational, legal, financing, and governance expertise to help the company advance its mission of developing transformative therapies for patients.""We are thrilled to welcome Ty Howton to the BioGene Therapeutics Board of Directors," said Stephen Van Deventer, Chairman and CEO of BioGene Therapeutics. "Ty brings exceptional operational leadership, deep legal and governance expertise, and a proven track record of scaling gene therapy companies from clinical to commercial stages. His extensive experience in financing, corporate development, and board-level oversight will be invaluable as we advance our pipeline and continue building BioGene into a leading gene therapy company."The Company has granted 100,000 stock options (each, an "Option") to Mr. Howton, with each Option exercisable into one common share of the Company (each, a "Share") at an exercisable price of $5.00 per Share until June 5, 2031. The Company has also granted Mr. Howton 500,000 restricted share units (each, an "RSU"). The Options and the RSUs vest in 25% increments on June 5, 2026, June 5, 2027, June 5, 2028, and June 5, 2029, respectively. About PreveCeutical Medical Inc.PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.About BioGene Therapeutics Inc. BioGene Therapeutics Inc. ("BioGene") is a Texas-based life sciences company focused on advancing innovative therapies in metabolic health and gene-based treatments. As a key component of BioGene's expansion, BioGene Australia operates as a wholly-owned subsidiary of BioGene in Texas, leveraging the strategic benefits of Australia's 43.5% R&D tax cashback incentive. This subsidiary supports ongoing research and development activities in Australia, where BioGene capitalizes on exceptional scientific talent and the nation's commitment to advancing life sciences. Currently, BioGene Australia is engaged in pioneering research into GLP-1 receptor agonists and advanced diabetes treatments, including gene therapies designed to address the growing global diabetes and obesity crisis.On Behalf of the Board of Directors,
PreveCeutical Medical Inc. & BioGene Therapeutics Inc.
"Stephen Van Deventer"
Chairman & Chief Executive Officer For further information, please contact:
Stephen Van Deventer
(604) 306-9669
info@PreveCeutical.comForward-Looking Statements:Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300463 Original: BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors

PreveCeutical Announces Extension of Non-Brokered Private PlacementMay 19, 2026 7:36 PM
NewsfileVancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated May 12, 2026 and April 22, 2026, it has extended the closing of its private non-brokered private placement (the "Offering") of units of the Company (each, a "Unit") to raise gross proceeds of $1,000,000 to June 12, 2026 and intends to close a second tranche of the Offering on or before June 12, 2026.Each Unit is comprised of one (1) common share (each, a "Share") in the capital of the Company and one-half (1/2) of one Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant entitles the holder thereof to purchase an additional Share (each, a "Warrant Share") at an exercise price of $0.05 per Warrant Share for a period of two years from the closing of Offering, subject to an acceleration right, whereby the expiry date of the Warrants may be accelerated if the daily closing price of the Shares equals or exceeds $0.10 or greater on the Canadian Securities Exchange ("CSE") (or such other recognized securities exchange on which the Shares may then trade) for a minimum of ten consecutive trading days, in which event the Company may accelerate the expiry of the Warrants by giving notice via news release and, in such case, all of the then unexercised Warrants will expire on the 30th day after the date on which the news release is disseminated.Finder's fees may be paid in connection with the Offering. The Company intends to use the aggregate gross proceeds from the sale of the Offering for short loan repayments, audit, accounting and legal fees, patents and further studies and analysis of rodents and tissues and general working capital purposes. All securities issued in connection with the Offering will be subject to a statutory hold period expiring four months and one day after the Closing. Completion of the Offering remains subject to certain conditions, including, without limitation, confirmation of no objection from the CSE.The securities issued under the Offering will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.About PreveCeuticalPreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.On behalf of the Board of Directors of PreveCeutical 
Stephen Van Deventer, Chairman and Chief Executive Officer For further information, please contact:Stephen Van Deventer: 
+1 604 306 9669 
Or Investor Relations 
ir@preveceutical.comNeither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.Forward-Looking Statements:This news release includes certain "forward-looking statements" under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements with respect to the expectations of management regarding the use of proceeds of the Offering and the closing of a subsequent tranche of the Offering. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements including that the proceeds of the Offering may not be used as stated in this news release, that the Company may not be able to close a subsequent tranche of the Offering and those additional risks set out in the Company's public documents filed on SEDAR+ at www.sedarplus.ca. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/298125 Original: PreveCeutical Announces Extension of Non-Brokered Private Placement

PreveCeutical Closes Initial Tranche of Non-Brokered Private PlacementMay 12, 2026 5:02 PM
NewsfileVancouver, British Columbia--(Newsfile Corp. - May 12, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news release dated April 22, 2026, it has closed an initial tranche (the "Initial Tranche") of its previously announced $1,000,000 non-brokered private placement (the "Offering"), which Initial Tranche consisted of the issuance of 13,600,000 units (each, a "Unit") of the Company at a price of $0.025 per Unit for gross aggregate proceeds of $340,000.Each Unit is comprised of one (1) common share (each, a "Share") in the capital of the Company and one-half (1/2) of one Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant entitles the holder thereof to purchase an additional Share (each, a "Warrant Share") at an exercise price of $0.05 per Warrant Share for a period of two years from the closing of the Initial Tranche (the "Initial Tranche Closing"), subject to an acceleration right, whereby the expiry date of the Warrants may be accelerated if the daily closing price of the Shares equals or exceeds $0.10 or greater on the Canadian Securities Exchange ("CSE") (or such other recognized securities exchange on which the Shares may then trade) for a minimum of ten consecutive trading days, in which event the Company may accelerate the expiry of the Warrants by giving notice via news release and, in such case, all of the then unexercised Warrants will expire on the 30th day after the date on which the news release is disseminated (the "Acceleration Right").In connection with the Initial Tranche Closing, the Company paid finders fees to three eligible finders comprised of $23,600 in cash and issued 944,000 finder's warrant (each, a "Finder's Warrant"). The Finder's Warrant are exercisable into one additional Share at an exercise price of $0.05 per Share for two years from the Initial Tranche Closing, subject to the Acceleration Right. The Company intends to use the aggregate gross proceeds of the Initial Tranche to pay outstanding payables, for operating expenses and for general working capital purposes.PreveCeutical intends to close a second tranche for the remainder of the Offering in the coming weeks.All securities issued in relation to the Initial Tranche are subject to a hold period expiring four months and one day after the Initial Tranche Closing, in accordance with applicable securities laws.The securities issued under the Offering, including those in the Initial Tranche, have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.About PreveCeuticalPreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.On behalf of the Board of Directors of PreveCeutical 
Stephen Van Deventer, Chairman and Chief Executive Officer For further information, please contact:
Stephen Van Deventer: 
+1 604 306 9669 
Or Investor Relations 
ir@preveceutical.comNeither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.Forward-Looking Statements:This news release includes certain "forward-looking statements" under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements with respect to the expectations of management regarding the use of proceeds of the Initial Tranche and the closing of a subsequent tranche of the Offering. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements including that the proceeds of the Initial Tranche may not be used as stated in this news release, that the Company may not be able to close a subsequent tranche of the Offering and those additional risks set out in the Company's public documents filed on SEDAR+ at www.sedarplus.ca. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/297224 Original: PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement

PreveCeutical Announces Non-Brokered Private PlacementApril 22, 2026 3:00 AM
NewsfileNOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - April 22, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 40,000,000 units (each, a "Unit") in the capital of the Company at a price of $0.025 per Unit for gross proceeds of up to $1,000,000. Each Unit consists of one (1) common share of the Company (each, a "Share") and one-half (1/2) of one Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant entitles the holder thereof to purchase an additional Share (each, a "Warrant Share") at an exercise price of $0.05 per Warrant Share for a period of two years from the closing of the Offering (the "Closing"); provided that the expiry of the Warrants can be accelerated if the closing price of the Company's common shares on the Canadian Securities Exchange (the "CSE") is $0.10 or greater for a minimum of ten consecutive trading days, and a notice of acceleration is provided in accordance with the terms of the Warrants. Finder's fees may be paid in connection with the Offering. The Company intends to use the aggregate gross proceeds from the sale of the Offering for short loan repayments, audit, accounting and legal fees, patents and further studies and analysis of rodents and tissues and general working capital purposes. All securities issued in connection with the Offering will be subject to a statutory hold period expiring four months and one day after the Closing. Completion of the Offering remains subject to certain conditions, including, without limitation, confirmation of no objection from the CSE.The securities issued under the Offering will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.About PreveCeuticalPreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.On behalf of the Board of Directors of PreveCeutical
Stephen Van Deventer, Chairman and Chief Executive Officer
For further information, please contact:Stephen Van Deventer: +1 604 306 9669
Or Investor Relations
ir@preveceutical.comNeither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.Forward-Looking Statements:This news release includes certain "forward-looking statements" under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements with respect to the expectations of management regarding the proposed Offering, the expectations of management regarding the use of proceeds of the Offering, closing conditions for the Offering, the expiry of hold periods for securities distributed pursuant to the Offering and other statements regarding the company's proposed business plans. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements including that: the Company may not complete the Offering on terms favorable to the Company or at all; the proceeds of the Offering may not be used as stated in this news release; the Company may be unable to satisfy all of the conditions to the Closing; and those additional risks set out in the Company's public documents filed on SEDAR+ at www.sedarplus.ca. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/293767
Original: PreveCeutical Announces Non-Brokered Private Placement

PreveCeutical Medical Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as DirectorMarch 30, 2026 3:00 AM
NewsfileVancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce the appointment of Dr. Raj S. Pruthi, MD, MHA, FACS, to its Board of Directors.Dr. Pruthi is an accomplished physician-scientist and executive with more than 20 years of experience spanning academic medicine, global pharmaceutical leadership, and biotechnology innovation. In his new role, he will contribute to shaping the Company's clinical development strategy and advancing key initiatives, including its Sol-gel program, Nature Identical™ peptide platform, non-addictive pain management therapies, and dopamine-based treatments targeting Parkinson's disease.Bringing extensive experience in clinical trial design, regulatory strategy, and organizational leadership, Dr. Pruthi has worked closely with global regulatory agencies such as the FDA and EMA and has been actively involved in capital markets initiatives. He currently serves as Chief Medical Officer of Relmada Therapeutics, Inc., a position he has held since June 2025. There, he leads development of the NDV-011 bladder cancer program, including a Phase 2 study and preparations for a global Phase 3 registrational trial expected to commence in early 2026. His responsibilities have included stakeholder engagement, trial execution, and collaboration with investors and regulatory authorities. He also played a central role in financing efforts that generated over $100 million through a public offering and an additional $160 million via a PIPE transaction.From 2022 to 2024, he held senior leadership roles in oncology at Johnson & Johnson Innovative Medicine (Janssen), where he contributed to late-stage clinical development, including multiple Phase 3 trials and regulatory submissions. His work supported approvals from both the FDA and EMA, including the approval of TAR-200 in 2025 for certain bladder cancer patients. He also incorporated patient-reported outcomes and digital health tools into clinical study designs.Before transitioning to industry, Dr. Pruthi spent over two decades in academia, serving as a tenured professor and Chair of Urology at leading institutions such as the University of California, San Francisco and the University of North Carolina. He is recognized for pioneering robotic surgical techniques and has shared his expertise internationally. His academic record includes more than 220 peer-reviewed publications, numerous book chapters, and hundreds of scientific presentations, along with leadership roles in national clinical guideline development.Dr. Pruthi received his medical degree from Duke University, completed his surgical and urology training at Stanford University, and earned a Master of Health Administration from the University of North Carolina at Chapel Hill. He is board-certified in urology and a Fellow of the American College of Surgeons."I am excited to join PreveCeutical at an important stage of its evolution," said Dr. Pruthi. "The Company's commitment to developing innovative therapies based on natural and nature-identical compounds aligns closely with my professional interests. I look forward to working with the team to advance its clinical programs and address significant unmet medical needs."Stephen Van Deventer, Chairman and CEO of PreveCeutical, added: "We are very pleased to welcome Dr. Pruthi to our Board. His extensive experience in clinical development, regulatory strategy, and leadership will be invaluable as we continue to advance our pipeline. His expertise strengthens our ability to deliver innovative therapies and achieve meaningful progress across our programs."About PreveCeutical Medical Inc.PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.On Behalf of the Board of Directors,
PreveCeutical Medical Inc.
"Stephen Van Deventer"
Chairman & Chief Executive Officer For further information, please contact:
Stephen Van Deventer
(604) 306-9669
info@PreveCeutical.comForward-Looking Statements:This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future, including, without limitation, the continued research interests of PreveCeutical, PreveCeutical's anticipated business plans, and its prospects of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "will", "pro forma", "plans", "expects", "may", "should", "budget", "schedules", "estimates", "forecasts", "intends", "anticipates", "believes", "potential", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding PreveCeutical, including expected growth, results of operations, including PreveCeutical's research and development activities, performance, industry trends, growth opportunities, that PreveCeutical will be granted requisite expedited approvals by world health, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights needed to carry out future business activities.Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to: complexities and delays in connection with research and development activities and the actual results of research and development activities; the ability of PreveCeutical to, among other things, protect its respective intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities and obtaining expedited requisite approvals from world health agencies; and the ability of PreveCeutical to commercialize products, pursue business partnerships, complete their research programs as planned, and obtain the financing required to carry out their planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry may also adversely affect the future results or performance of PreveCeutical. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, PreveCeutical assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although PreveCeutical believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by PreveCeutical from time-to-time. These reports and PreveCeutical's filings are available at www.sedarplus.ca. Neither the Canadian Securities Exchange (CSE or CNSX Markets), its Regulation Services Provider (as that term is defined in policies of the CSE), nor any other regulatory authority accepts responsibility for the adequacy or accuracy of this release.Any link in this press release to external information or other resources is provided for reference only, and such information or resources might change from time to time, and may include forward-looking statements as described above, and are subject to the above disclaimers under this heading forward-looking statements.Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290425
Original: PreveCeutical Medical Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director

PreveCeutical advances drug delivery tech with Sol-Gel platform, eyes multi-asset spinouts | CSE:PREV, OTCQB:PRVCF https://t.co/1Fz1IFK780— Stephen Van Deventer (@DeventerStephen) March 25, 2026

BioGene Therapeutics Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as DirectorMarch 12, 2026 3:00 AM
NewsfileVancouver, British Columbia--(Newsfile Corp. - March 12, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H0) ("PreveCeutical"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, today announced that BioGene Therapeutics Inc. (the "Company"), a company that it is a significant shareholder of, has appointed Raj S. Pruthi, MD, MHA, FACS, as a Director of the Company. Dr. Pruthi, a renowned physician-scientist, executive leader, and board-level strategist with over two decades of experience in academic medicine, global pharmaceutical leadership, and biotechnology innovation, will lead BioGene's clinical strategy and advance its innovative gene therapy programs targeting metabolic disorders such as diabetes and obesity.Dr. Pruthi brings deep expertise in registrational clinical trial design and execution, global regulatory engagement (FDA and EMA), capital markets strategy, and cross-functional leadership. Most recently, as Chief Medical Officer at Relmada Therapeutics, Inc. since June 2025, he has led the development of the NDV-011 program for bladder cancer, overseeing a Phase 2 open-label study and preparations for a multinational Phase 3 registrational trial set to begin in the first half of 2026. In this role, he managed KOL engagement, site recruitment, patient assessments, and execution, while also contributing to external engagements with investors, patient advocacy groups, and regulatory bodies. Dr. Pruthi played a key role in a public offering that raised over $100 million in net proceeds, extending the company's cash runway into 2028, and, most recently a PIPE that raised an additional $160 million.Prior to Relmada, Dr. Pruthi served as Chief Medical Officer at enGene Inc. from April 2024 to June 2025, where he spearheaded a global gene therapy registrational program for bladder cancer across over 60 countries, including North America, Europe, and APAC, with a planned BLA submission in 2026. He grew the medical and clinical development teams from 5 to nearly 20 members, managing a $32 million annual budget and overseeing CRO performance.From September 2022 to April 2024, Dr. Pruthi was Senior Global Medical Affairs Leader for Bladder Cancer and Senior Medical Director in Oncology at Johnson & Johnson Innovative Medicine (Janssen), where he authored three large Phase 3 trials (400-500 patients each) for evidence generation and registrational purposes. He contributed to FDA and EMA approvals, including the FDA approval of TAR-200 in September 2025 for BCG-unresponsive non-muscle invasive bladder cancer, and integrated patient-reported outcomes, digital health, and remote monitoring into study designs.Before his industry transition, Dr. Pruthi had a distinguished academic career from March 2000 to September 2022, serving as a tenured Professor and Department Chair of Urology at leading institutions including the University of California, San Francisco (UCSF) and the University of North Carolina (UNC). He pioneered robotic surgical techniques, such as robotic radical cystectomy and intracorporeal urinary diversion, and performed them as a Visiting Professor in Europe, China, and South Korea. His academic contributions include over 220 peer-reviewed publications, more than 20 book chapters, over 420 scientific presentations, and leadership in national guideline development, including the AUA Bladder Cancer Guidelines Committee since 2004.Dr. Pruthi has held numerous national leadership roles, including Past-President and President of the Society of Academic Urology, Chair of the Advisory Council for Urology at the American College of Surgeons, Chair of the AUA Publications Committee, and membership in prestigious societies such as the American Association of Genitourinary Surgeons and the Clinical Society of Genitourinary Surgeons. He has been recognized with awards such as "Best Doctors in America" annually from 2013 to 2021, Castle Connolly's "America's Top Doctors," and multiple teaching excellence honours.Committed to diversity, equity, and inclusion (DEI), Dr. Pruthi has championed diverse leadership in urology, noting that at UCSF, 25% of faculty and 44% of residents were female-exceeding national averages. His efforts include health services research on racial disparities in cancer care and initiatives to increase opportunities for underrepresented minorities.In education and mentorship, Dr. Pruthi has mentored residents, fellows, and faculty, emphasizing personalized career development. At UCSF and UNC, he expanded residency programs, implemented innovative training tools like app-based feedback and surgical simulations, and fostered a culture of faculty wellness and development, resulting in high satisfaction rates and successful graduate outcomes.Dr. Pruthi earned his MD from Duke University School of Medicine, completed surgical and urology training at Stanford University, and holds a Master of Health Administration from UNC Chapel Hill. He is board-certified by the American Board of Urology and a Fellow of the American College of Surgeons."I am thrilled to join BioGene Therapeutics at this pivotal time in its growth," said Dr. Raj S. Pruthi. "The Company's focus on dual gene therapy for metabolic health aligns perfectly with my passion for innovative, patient-centered solutions. Drawing from my experience in leading global registrational trials, regulatory strategies, and team building in gene therapy and oncology, I look forward to collaborating with the team to accelerate the Company's clinical programs and deliver transformative therapies for diabetes and obesity, addressing unmet needs in preventive and curative medicine."Stephen Van Deventer, Chairman and CEO of PreveCeutical Medical Inc., commented, "We are delighted to welcome Dr. Pruthi to BioGene Therapeutics. His proven track record in gene therapy, regulatory strategy, clinical trial execution, and academic leadership will be instrumental as we advance our pipeline. Raj's expertise in scaling teams, securing funding, and driving FDA approvals strengthens our leadership and positions BioGene for success in developing cutting-edge treatments that leverage nature and science for better health outcomes."The Company has granted 100,000 stock options (each, an "Option") to Dr. Pruthi with each Option exercisable into one common share of the Company (each, a "Share") at an exercisable price of $5.00 per Share until March 10, 2030. The Company has also granted Dr. Pruthi 500,000 restricted share units (each, an "RSU"). The Options and the RSUs vest as to 25% on March 10, 2026, 25% on March 10, 2027, 25% on March 10, 2028 and 25% on March 10, 2029. About PreveCeutical Medical Inc.PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.About BioGene Therapeutics Inc. BioGene Therapeutics Inc. ("BioGene") is a Texas-based life sciences company focused on advancing innovative therapies in metabolic health and gene-based treatments. As a key component of BioGene's expansion, BioGene Australia operates as a wholly-owned subsidiary of BioGene in Texas, leveraging the strategic benefits of Australia's 43.5% R&D tax cashback incentive. This subsidiary supports ongoing research and development activities in Australia, where BioGene capitalizes on exceptional scientific talent and the nation's commitment to advancing life sciences. Currently, BioGene Australia is engaged in pioneering research into GLP-1 receptor agonists and advanced diabetes treatments, including gene therapies designed to address the growing global diabetes and obesity crisis.On Behalf of the Board of Directors,
PreveCeutical Medical Inc. & BioGene Therapeutics Inc.
"Stephen Van Deventer"
Chairman & Chief Executive Officer For further information, please contact:
Stephen Van Deventer
(604) 306-9669
info@PreveCeutical.comForward-Looking Statements:This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding the Company delivering transformative therapies for diabetes and obesity and the Company successfully developing cutting-edge treatments that leverage nature and science for better health outcomes. The forward-looking statements reflect management's current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements including adverse market conditions and other factors beyond the control of the parties. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company; regulations and policies affecting the biotechnology or pharmaceutical industry adversely affecting the future results or performance of PreveCeutical or BioGene; the Company's failure to obtain the required consents and approvals for the Acquisition and the Distribution; and the Company determining that the Distribution is not an optimal strategy following tax and business consultations. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288230
Original: BioGene Therapeutics Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director

PreveCeutical Announces Canadian Patent Office Allowance of Innovative Pain Therapy TechnologyFebruary 25, 2026 3:00 AM
NewsfileVancouver, British Columbia--(Newsfile Corp. - February 25, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce that the Canadian Patent Office has allowed Canadian Patent Application No. 3127020, titled "A Cyclic Peptide", which relates to the Company's pain therapy program. This allowance represents a significant milestone in the protection of PreveCeutical's proprietary technologies aimed at addressing unmet needs in pain management.The Canadian patent application is directed novel cyclized peptides that are analogues of dynorphin, an endogenous opioid peptide. These compounds are designed to deliver effective pain relief while potentially reducing the adverse effects commonly associated with traditional opioid therapies, such as dependence and tolerance. The invention also encompasses pharmaceutical compositions and methods of use for treating or preventing pain in subjects, reinforcing the therapeutic potential of this technology.This patent application is jointly owned by PreveCeutical Medical Inc. and The University of Queensland, reflecting the strength of the collaborative research partnership between the two organizations. Grant of the application is expected in Q2 2026 - the granted patent will provide exclusivity in Canada until January 2040, subject to maintenance, and forms part of a broader patent family with corresponding applications pending in the United States, Europe, and Australia. This global strategy ensures robust protection for PreveCeutical's intellectual property portfolio and supports its long-term commercialization objectives.PreveCeutical's pain therapy program focuses on developing next-generation peptide-based analgesics that aim to overcome the limitations of conventional opioids. By leveraging advanced peptide engineering and cyclization techniques, these candidates are designed to exhibit enhanced stability and receptor selectivity, which could significantly improve patient outcomes in managing acute and chronic pain.PreveCeutical's CEO, Stephen Van Deventer, commented: "The approval of this application is a significant milestone for PreveCeutical, reaffirming our commitment to pioneering next-generation solutions in pain management. This intellectual property bolsters our position in a global market demanding safer alternatives to opioids and supports our long-term path to commercialization."Further details on the patent can be accessed through the Canadian Patent Search at https://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/3127020/summary.html.About PreveCeuticalPreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.On behalf of the Board of Directors of PreveCeutical Stephen Van Deventer, Chairman and Chief Executive Officer For further information, please contact:
Stephen Van Deventer: +1 604 306 9669
Or Investor Relations ir@preveceutical.comNeither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.Forward-Looking Statements:This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future, including, without limitation, the continued research interests of PreveCeutical, PreveCeutical's anticipated business plans, and its prospects of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "will", "pro forma", "plans", "expects", "may", "should", "budget", "schedules", "estimates", "forecasts", "intends", "anticipates", "believes", "potential", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding PreveCeutical, including expected growth, results of operations, including PreveCeutical's research and development activities, performance, industry trends, growth opportunities, that PreveCeutical will be granted requisite expedited approvals by world health, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights needed to carry out future business activities.Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to: complexities and delays in connection with research and development activities and the actual results of research and development activities; the ability of PreveCeutical to, among other things, protect its respective intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities and obtaining expedited requisite approvals from world health agencies; and the ability of PreveCeutical to commercialize products, pursue business partnerships, complete their research programs as planned, and obtain the financing required to carry out their planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry may also adversely affect the future results or performance of PreveCeutical. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, PreveCeutical assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although PreveCeutical believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by PreveCeutical from time-to-time. These reports and PreveCeutical's filings are available at www.sedarplus.ca. Neither the Canadian Securities Exchange (CSE or CNSX Markets), its Regulation Services Provider (as that term is defined in policies of the CSE), nor any other regulatory authority accepts responsibility for the adequacy or accuracy of this release.Any link in this press release to external information or other resources is provided for reference only, and such information or resources might change from time to time, and may include forward-looking statements as described above, and are subject to the above disclaimers under this heading forward-looking statements.Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285236
Original: PreveCeutical Announces Canadian Patent Office Allowance of Innovative Pain Therapy Technology

PreveCeutical Medical Inc. is led by a team with extensive experience in pharmaceutical R&D, corporate finance, and business development. The leadership includes veterans from global pharmaceutical companies and specialized research institutions.
Executive Leadership & Board
Stephen Van Deventer (Chairman, CEO & Interim CFO): An experienced business person and corporate director with over 30 years in international corporate relations and business development. He specializes in launching small to medium-sized companies into public markets.
Dr. Makarand (Mak) Jawadekar (President & Chief Science Officer): A former director at Pfizer Inc., where he worked for 28 years. His expertise includes drug delivery technology assessment, portfolio management, and creating external partnerships for drug delivery.
Dr. Harendra (Harry) Parekh (Chief Research Officer): Based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), where he heads the Drug/Gene Delivery Group.
C. Evan Ballantyne (Director): A finance executive with 20 years of experience as a CFO in the healthcare industry, including roles at OncXerna Therapeutics and Orchestra BioMed, where he closed deals valued at over $200 million.
Kathleen Rokita (Director): A CPA and finance executive with extensive experience in operations and strategy for large medical groups.
PreveCeutical Medical Inc.
Scientific & Advisory Team
Dr. Francis Tavares (Chief Technology Officer): Has extensive experience in the preclinical development of small molecule inhibitors and was the founder and CEO of ChemoGenics BioPharma.
Stephen Glover (Corporate Advisor): An industry veteran with over 30 years of leadership at companies like GSK, Roche, and Amgen. He has overseen the launch of over 25 products and held leadership roles in companies that created billions in shareholder value.
Dr. Bryan Jones (Advisor): Former VP of Operations at Sorrento Therapeutics and COO of Aardvark Therapeutics, with a PhD in Genetics.
PreveCeutical Medical Inc.
Subsidiary Leadership (BioGene Therapeutics Inc.)
Dr. Mariya Georgieva (President): Appointed in November 2024, she joined from AstraZeneca, where she served as Director of Diagnostic Alliances within Precision Medicine R&D.

Based on recent company developments, PreveCeutical Medical (CSE: PREV, OTCQB: PRVCF) appears focused on R&D milestones, IP portfolio expansion, and strategic corporate restructuring. Key catalysts that could drive the share price upward include:
Clinical Success of CNS-Active Drug Delivery: A major catalyst is the successful development of their novel method for delivering drugs directly through the blood-brain barrier. A February 2026 patent filing for this, particularly for Parkinson's disease, aims to provide an alternative to traditional, less effective treatments, which could significantly boost investor confidence.
Granting of Patents: The company is actively securing intellectual property, such as the December 2025 patent grant for their non-addictive analgesic pain therapy, which helps to validate their technology and build asset value.
Post-Spinout Focus on Core Programs: Following the spin-off of its Dual Gene Therapy program to BioGene Therapeutics, which closed in November 2025, PreveCeutical now focuses on its remaining portfolio, including the Sol-gel program, Nature Identical™ peptides, and concussions/traumatic brain injury treatment. Demonstrating progress in these areas is crucial for re-rating the stock.
Successful Capital Financing: The company has recently increased its non-brokered private placement financing to $1.2 million, as of October 2025. The ability to secure funding without significant dilution, or by attracting institutional investors, is a positive catalyst for share price stability and growth.
Strategic Partnerships: Further partnerships, similar to the arrangement with BioGene, to expand market reach and commercialize their intellectual property could act as significant valuation inflection points.

PreveCeutical Announces Filing of Patent for Delivery of CNS-Active AgentsFebruary 9, 2026 3:00 AM
NewsfileVancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce it has filed an International (PCT) patent application on February 5, 2026, having the application no. PCT/US2026/014110, and entitled "Delivery of CNS-active therapeutic agents".The international patent application covers innovative methods and formulations aimed at addressing longstanding challenges in the treatment of neurological diseases and disorders. Of particular interest is Parkinson's disease, which is a neurodegenerative condition afflicting over 10 to 12 million globally, and it is cited as the 2nd most common neurodegenerative disorder after dementia. Progressive symptoms of Parkinson's disease include unilateral movement issues, typically presenting as a slight tremor and quiet speech in the early stages, through to severe disability that impacts eating, bathing and dressing, complemented by cognitive decline. Depletion of the neurotransmitter dopamine in the brain is the key driver of Parkinson's. Direct supplementation with dopamine is not currently a viable option, due to it being unable to cross the blood-brain barrier, and treatments most typically involve oral administration of the dopamine precursor, levodopa (L-dopa). As Parkinson's is a progressive disease also impacting the health of dopaminergic neurons, their gradual decline in numbers is inevitable, reaching a threshold that renders supplementation with L-dopa ineffective. PreveCeutical has now developed an approach for the delivery of central nervous system (CNS)-active drugs, such as dopamine, directly to the brain, and formulations that are adapted for this delivery mode. By supplying the native neurotransmitter (dopamine) directly to the brain, the Company proposes circumventing the need to administer L-dopa, dopamine agonists and other therapeutics progressively prescribed for the management of Parkinson's across the spectrum of disease. Furthermore, this approach has the potential to offer patients in the advanced stages of Parkinson's a safe and effective treatment option, through direct replenishment of dopamine in the brain, potentially circumventing the need for advanced/invasive treatments.More broadly, PreveCeutical's novel approach has the potential to address historical bottlenecks in the delivery of a range of peripherally-restricted therapeutics for CNS conditions, and it is actively exploring options to exploit these opportunities.Commenting on the filing, PreveCeutical Chief Executive Officer Stephen Van Deventer stated, "Despite decades of research, there is still no proven clinical strategy for delivering dopamine directly to the brain. Our technology aims to change that, and we believe it represents an important step toward transforming the treatment landscape for Parkinson's disease and other central nervous system disorders."The Company is not making any express or implied claims that its product and approach has the ability to manage Parkinson's disease at this time.Although PreveCeutical believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate or successful.About PreveCeuticalPreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.On behalf of the Board of Directors of PreveCeutical 
Stephen Van Deventer, Chairman and Chief Executive Officer For further information, please contact:
Stephen Van Deventer: +1 604 306 9669
Or Investor Relations ir@preveceutical.comNeither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.Forward-Looking Statements:Certain information in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements in this news release include: that the Company's patent will be successfully granted by the regulators; that the Company's technology for delivering drugs directly to the brain by directly crossing the blood-brain barrier will be successful and that the Company's technology will be a treatment for Parkinson's disease or have any positive effects on those with Parkison's disease. Forward-looking information is based on reasonable assumptions that have been made by PreveCeutical as at the date of such information and is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of PreveCeutical to be materially different from those expressed or implied by such forward-looking information, including but not limited to: the risk of PreveCeutical not obtaining the patent applied for; the risk that the technology which is the subject of the patent not successfully working for the administration of drugs directly through the blood-brain barrier; the risk that the Company will not have access to the necessary capital to operate its business; the accuracy of PreveCeutical's projections and estimates; interest and exchange rates; competition; share price fluctuations; actual results of activities; government regulation; political or economic developments; environmental risks; insurance risks; capital expenditures; operating or technical difficulties in connection with research and development activities; personnel relations; changes and volatility in project parameters as plans continue to be refined; the inherent uncertainties regarding cost estimates, financing, cost overruns, availability of materials and equipment, timeliness of government approvals, taxation, political risk and related economic risk; global financial conditions; the market price of PreveCeutical's securities; ability to access capital; changes in interest rates; liabilities and risks inherent in research and development operations; the potential influence of or reliance upon PreveCeutical's business partners, and the adequacy of insurance coverage. Forward-looking information is based on certain assumptions that PreveCeutical believes is reasonable, including that the technology which is the subject of the patent is successful in the administration of drugs directly through the blood-brain barrier; sufficient working capital will be available for operation of the business; that the general business and economic conditions will not change in a material adverse manner, that financing will be available if and when needed on reasonable terms and that PreveCeutical will not experience any material labour dispute, accident, or failure of plant or equipment, as well as the risks and uncertainties which are more fully described in the Company's annual and quarterly management's discussion and analysis and in other filings made by the Company with Canadian securities regulatory authorities under the Company's SEDAR+ profile. Although PreveCeutical has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. PreveCeutical does not undertake to update any forward-looking information contained herein or that is incorporated by reference herein, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283161
Original: PreveCeutical Announces Filing of Patent for Delivery of CNS-Active Agents

Very interesting Walter. We haven’t heard much about the therapy for concussions. I didn’t think they were still working on that.

We are definitely due from some updates on Sol gel, BioGene and pain therapy.

For the Parkinson’s treatment through the Sol gel I believe they have to wait for patents to be filed so they don’t get nulled. Which should come soon.

I wonder if Biopain spin out will come in 2026. I think there’s a lot to work on for now, with the BioGene one that was completed end of 2025 I think we will have to wait for Biopain.

BioGene should have news/update in the near future too. I had read in the information circular last September that they were working on bridge financing with parent company (prev). So hopefully this or maybe a partnership to get the program going faster.

There’s definitely a lot going on, so once we have partnerships/financing or some sort there will be more movement.

In preclinical rat studies PreveCeutical and Endosane demonstrated that their nose-to-brain sol-gel delivery system significantly improves CBD uptake and retention compared to traditional methods.
Key findings regarding brain delivery and retention include:
Direct Central Nervous System (CNS) Access: The sol-gel formulation bypasses the blood-brain barrier and liver metabolism by adhering to the nasal mucosal tissue.
Rapid Onset: Intranasal administration of the sol-gel leads to a rapid increase in CBD concentrations within the brain.
Enhanced Retention: Unlike liquid sprays, the sol-gel formulation "gels" upon contact with the nasal cavity, allowing it to remain at the target site for sustained drug release for up to seven days.
Improved Bioavailability: By avoiding first-pass metabolism in the liver, the technology achieves higher potency and controlled pharmacological release directly to the brain.
Cognitive Rescue: In specific disease models, such as rats prenatally exposed to THC, CBD administration helped normalize impaired memory scores and fine-tuned hippocampal markers of synaptic plasticity.
Marker Identification: The collaboration identified anandamide as a potential blood surrogate marker for measuring CBD's activity within the brain.

Most likely news to emerge for PreveCeutical in 2026:
Sol-Gel Product Development and Licensing: After filing a provisional patent for a Sol-gel cannabinoid formulation, the company is likely to report on partnerships, licensing agreements, or developmental milestones for this nasal drug delivery system, especially regarding its "nose-to-brain" (N2B) platform for neurological conditions, including a recently initiated project for Parkinson's disease.
Intellectual Property and Patent Updates: Following a recent patent grant for its pain therapy technology, additional news regarding the approval or progression of its "Nature Identical™" peptide patents in other jurisdictions (U.S., Europe, Canada) is expected.
Progress in Non-Addictive Analgesics: Updates on pre-clinical evaluations for their non-addictive analgesic peptides, designed to replace addictive opioids like fentanyl and morphine, are highly probable as they look for commercialization partners.
Commercialization of Concussion Therapy: News regarding the progress of their therapeutic product targeting athletes and individuals suffering from concussions (mild traumatic brain injury).
Financing and Corporate Structure News: Following the 2025 spin-out, the company may release news on further non-brokered private placements to fund R&D and maintain operational liquidity.
Post-Spinout Operational Updates: Updates regarding the independent operation of PreveCeutical and its new, narrowed focus on its five core, non-gene therapy, R&D programs.

core of PreveCeutical's current strategy is to move its research and development (R&D) programs into separate companies. This allows each new entity to focus on its specific area and offers PreveCeutical shareholders exposure to multiple assets.
BioGene Therapeutics Inc.: The first spin-off, completed in November 2025, involved transferring the intellectual property for the dual gene therapy program targeting diabetes and obesity to BioGene. PreveCeutical distributed a portion of BioGene shares to its existing shareholders. BioGene is expected to list publicly by the end of 2025.
BioPain: A second spin-out is in the planning stages for mid-2026. This entity will focus on the company's non-addictive analgesic peptides program, which aims to provide alternatives to conventional opioids for pain management.
Research and Development Focus
Following the spin-off of the gene therapy program, PreveCeutical continues to advance its remaining R&D programs:
Non-Addictive Pain Management: A significant focus is on developing peptide-based analgesics that are potentially non-addictive and comparable in potency to morphine. A patent for this technology was recently granted in Australia.
Sol-gel Technology: The company is developing a soluble gel delivery system, including an N2B (nose-to-brain) platform for potential use in treating conditions like Parkinson's disease and concussions.
Nature Identical™ Peptides: R&D continues on peptides for various other ailments.

Correction. Sock must be purchased by tomorrows close for it to clear for Friday to get BioGene

Same type of share distribution plan for the spin out of Biopain is next

https://www.preveceutical.com/_resources/info_circ_preveceutical_2025.pdf pg 96 biogene to ipo @ $5 per share. For every 1 mil of preveceutical shares owned will receive 20,000 biogene shares. Oct 31 at the close of day is the deadline.

https://finance.yahoo.com/news/preveceutical-provides-plan-arrangement-biogene-110000058.html

https://finance.yahoo.com/news/biogene-therapeutics-inc-appoints-dr-110000584.html

https://www.streetwisereports.com/article/2025/06/06/biotech-company-unlocks-gene-therapy-breakthrough-in-canada.html#:~:text=PreveCeutical%20Preventive%20Health%20Sciences%20(PREV,studies%20signaling%20major%20delivery%20breakthroughs.

https://www.ainvest.com/news/preveceutical-700k-private-placement-fuels-breakthroughs-sol-gel-metabolic-therapies-time-invest-2505/

https://www.biospace.com/press-releases/preveceutical-to-develop-sol-gel-n2b-platform-for-parkinsons-disease

https://www.newsfilecorp.com/release/236289/BioGene-Therapeutics-to-Participate-in-the-43rd-JP-Morgan-Healthcare-Conference

https://preveceutical.com/

https://www.biospace.com/press-releases/biogene-therapeutics-welcomes-stephen-glover-to-its-board-of-directors

https://www.biospace.com/press-releases/biogene-therapeutics-welcomes-professor-mirela-delibegovic-frse-to-its-scientific-advisory-board

https://www.newsfilecorp.com/release/231211/BioGene-Therapeutics-Welcomes-Dr.-Deepak-Sampath-PhD.-to-Its-Board-of-Directors

https://www.stocktitan.net/news/PRVCF/preve-ceutical-s-subsidary-biogene-therapeutics-announces-strategic-gdo2jzec33e4.html

https://www.newsfilecorp.com/release/230196/PreveCeutical-Announces-Closing-of-BioGene-Therapeutics-Transaction

https://www.biospace.com/press-releases/preveceutical-launches-strategic-partnership-with-biogene-therapeutics

Looking forward to some news here.

https://finance.yahoo.com/news/rnai-therapeutics-market-size-expected-150200704.html

Check out Stephen Van Deventer on X.
Buss & family man. “The difference between good CEO & Great CEO. How CEO handles the storms” Chairman & CEO of @preveceuticals SEEK SAFE HARBOUR https://x.com/DeventerStephen

Pitch deck added to company website can be found by clicking "Investors" "presentations" https://www.preveceutical.com/

https://www.cnbc.com/2024/01/09/regeneron-ceo-says-gene-therapy-is-the-next-big-thing-for-biotech.html

https://www.cnbc.com/2024/01/05/cramer-names-biopharma-companies-as-industry-mergers-start-to-accrue.html

https://www.cnbc.com/2023/12/13/fed-interest-rate-decision-december-2023.html

Potential upcoming catalysts:
1. Endosane payment(s) related to sol gel
2. Funding secured
3. Announcement of partnership
4. Commencement of trials

Thx Walter

https://www.prnewswire.com/news-releases/preveceutical-initiates-preparation-of-proof-of-concept-preclinical-study-for-its-diabetes--obesity-dual-gene-therapy-program-302003747.html

https://www.marketscreener.com/quote/stock/PREVECEUTICAL-MEDICAL-INC-37333412/news/PreveCeutical-Medical-Inc-and-Endosane-Pharmaceuticals-GmbH-Announces-Innovative-Preclinical-Approa-44875494/

$PRVCF PreveCeutical Initiates Non-Analgesic (Painkiller) Program, Clinical Development Program & Disclosure Committee

https://www.newsfilecorp.com/release/158992

Vancouver, British Columbia--(Newsfile Corp. - March 20, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that PreveCeutical commenced clinical work with our selected clinical research organization (CRO) as announced on February 7, 2023, to complete the following.

Conduct a comprehensive gap analysis to both confirm current conclusions as well as identify any potential additional nonclinical studies (beyond those already underway or in the planning stage) that will be needed to support a successful initial IND and/or CTA submission.
Construction of a clinical development plan for Phase 1 through pivotal Phase 3 studies.
Authoring of the Investigational Brochure for the Client's lead peptide in the final indication of interest.
PreveCeutical has now commenced the clinical development on March 20, 2023. This work is being performed at our selected CRO's facilities in Australia.

Furthermore, the board of directors appointed a disclosure committee represented by Stephen Van Deventer, Dr Linnea Olofsson and Evan Ballantyne effective immediately.

PreveCeutical's Chief Executive Officer, Mr. Stephen Van Deventer, commented, "As we continue to meet further milestones, we are enthusiastic that this program has commenced as we plan to aggressively pursue the development so we may apply for IND (Investigative New Drug) status and complete the Phase 1 clinical trials."

Nice article posted today from Bezinga regarding $PREV and their solgel formula!
Check it out! Mr. Deventer posted it on Twitter a couple hours ago.

$PREV

Great news today! Things are starting to fall into place. Finally having this class action lawsuit settled and off $PREV back. Would like to see the share price start climbing and sticking with more good news.

$PREV

BIG NEWS today!

$PREV

$PRVCF-How could put up shit alike this opportunity if you catch me important give it up we sure it your in choice I'm gains? Your secularist your competency making a big deals about this that in check stay rightmost have no probables. A soundly about this timing I'm chilling you endurance fees it. The sounds call long is true in discovery.

All prophet for see a an is it is reflecting gains just keeps putting it up? Provence knowledge is power as indicated now timing call this right here well craft?

https://www.otcmarkets.com/.../PreveCeutical-Receives
...

Patience PAYS on this one.

It’ll pop soon.

Alternative ways to cure/help cancer patients is hot IMO.

https://ca.proactiveinvestors.com/companies/news/937693/preveceutical-files-provisional-australian-patent-application-for-blue-scorpion-venom-based-brain-cancer-treatment-937693.html